Literature DB >> 8664988

Differential responses of femoral and vertebral bones to long-term excessive L-thyroxine administration in adult rats.

S Suwanwalaikorn1, B Ongphiphadhanakul, L E Braverman, D T Baran.   

Abstract

Recent studies suggest that thyroid-stimulating hormone suppressive doses of thyroid hormone decrease bone mass in humans and growing rats. To determine the long-term effects of excessive L-thyroxine administration on the femur and vertebrae in an adult rat model, 20 male Sprague-Dawley rats (20 weeks old) were randomized into two groups. Group 1 received L-thyroxine (20 micrograms/100 g body weight ip daily), and group 2 received normal saline ip daily for 20 weeks. Femoral and lumbar vertebral bone mineral density measurements were performed at 0, 6, 15, 18 and 20 weeks of treatment. After 20 weeks of treatment, total RNA was isolated from both femoral and lumbar bones. Northern hybridization was performed with 32P-labeled DNA probes for osteocalcin, osteopontin, alkaline phosphatase and tartrate-resistant acid phosphatase. Significant decreases in bone mineral density in the femur of L-thyroxine-treated rats were observed after 15 weeks (p < 0.03). Lumbar bone mineral density was not affected. Both osteoblast (osteocalcin, osteopontin, alkaline phosphatase) and osteoclast (tartrate-resistant acid phosphatase) gene expression markers were increased significantly in the femoral bone (p < 0.001), but not in the lumbar vertebrae of the L-thyroxine-treated rats. We conclude that long-term administration of excessive doses of L-thyroxine to the adult rat preferentially affects femoral but not vertebral bone. This is manifested by decreased bone mineral density as well as increased gene expression markers for osteoblast and osteoclast activity in the femur.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8664988     DOI: 10.1530/eje.0.1340655

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  6 in total

1.  The Thyroid Hormone Transporter MCT10 Is a Novel Regulator of Trabecular Bone Mass and Bone Turnover in Male Mice.

Authors:  Franziska Lademann; Steffen Mayerl; Elena Tsourdi; Francois Verrey; Victoria D Leitch; Graham R Williams; J H Duncan Bassett; Lorenz C Hofbauer; Heike Heuer; Martina Rauner
Journal:  Endocrinology       Date:  2022-01-01       Impact factor: 5.051

Review 2.  Role of Thyroid Hormones in Skeletal Development and Bone Maintenance.

Authors:  J H Duncan Bassett; Graham R Williams
Journal:  Endocr Rev       Date:  2016-02-10       Impact factor: 19.871

3.  Constitutively Elevated Blood Serotonin Is Associated with Bone Loss and Type 2 Diabetes in Rats.

Authors:  Igor Erjavec; Tatjana Bordukalo-Niksic; Jelena Brkljacic; Danka Grcevic; Gordana Mokrovic; Maja Kesic; Dunja Rogic; William Zavadoski; Vishwas M Paralkar; Lovorka Grgurevic; Vladimir Trkulja; Lipa Cicin-Sain; Slobodan Vukicevic
Journal:  PLoS One       Date:  2016-02-23       Impact factor: 3.240

4.  Low TSH Levels Within Euthyroid Range Could Play a Negative Role on Bone Mineral Density in Postmenopausal Women with Type 2 Diabetes.

Authors:  Congying Liu; Junhong Pan; Song Wen; Thiquynhnga Nguyen; Dongxiang Xu; Chaoxun Wang; Xinlu Yuan; Zhongqiu Wen; Ligang Zhou
Journal:  Diabetes Metab Syndr Obes       Date:  2021-05-24       Impact factor: 3.168

5.  Bone Indices in Thyroidectomized Patients on Long-Term Substitution Therapy with Levothyroxine Assessed by DXA and HR-pQCT.

Authors:  Emil Moser; Tanja Sikjaer; Leif Mosekilde; Lars Rejnmark
Journal:  J Thyroid Res       Date:  2015-07-13

6.  Lack of α2C-Adrenoceptor Results in Contrasting Phenotypes of Long Bones and Vertebra and Prevents the Thyrotoxicosis-Induced Osteopenia.

Authors:  Marilia Bianca Cruz Grecco Teixeira; Gisele Miyamura Martins; Manuela Miranda-Rodrigues; Iasmin Ferreira De Araújo; Ricardo Oliveira; Patrícia Chakur Brum; Cecilia Helena Azevedo Gouveia
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.